年轻（<35岁）单倍体与老年（≥35岁）不匹配的无关供体，反之亦然，用于首次缓解的急性髓性白血病患者的移植后环磷酰胺同种异体干细胞移植：代表急性白血病工作组的一项研究欧洲血液和骨髓移植学会的会员。
Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
发表日期：2024 Aug 18
作者：
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Didier Blaise, Emanuele Angelucci, Jan Vydra, Lucía López Corral, Stefania Bramanti, Patrizia Chiusolo, Mi Kwon, Yener Koc, Maija Itäla-Remes, Massimo Martino, Alexander Kulagin, Alessandro Busca, Fabio Ciceri, Mohamad Mohty
来源：
Stem Cell Research & Therapy
摘要：
我们比较了 1065 名年轻（<35 岁）单倍体（Haplo）供体（yHaplo）与 147 名老年人（≥35 岁）错配捐献者在第一次完全缓解后接受 HSCT 的 AML 患者的移植（HSCT）结果无关捐赠者 (oMMUD)（第一次比较）以及 271 名年轻（<35 岁）MMUD (yMMUD) 与 1315 名老年（≥35 岁）Haplo 捐赠者 (oHaplo)（第二次比较）。 yHaplo 组与 oMMUD 组相比，急性移植物抗宿主病 (aGVHD) II-IV 级显着降低 (HR = 0.62，p = 0.007)。慢性GVHD、非复发死亡率（NRM）、复发率、无白血病生存期、总生存期以及无GVHD和无复发生存期没有显着差异。至于第二个比较，oHaplo 组中有更多患者患有新发 AML，分别为 86.6% 和 yMMUD 组的 81.9%（p = 0.044），而清髓性预处理在 yMMUD 组中使用频率更高，分别为 53.3% 和 46.8%。 oHaplo 组中的% (p = 0.049)。 yMMUD 组的 aGVHD II-IV 级和 NRM 显着低于 oHaplo 组（HR = 0.69，p = 0.013 和 HR = 0.60，p = 0.022）。所有其他移植结果均无差异。总之，来自年轻替代供者（<35 岁）的 HSCT 导致 II-IV 级 aGVHD 的发生率较低。此外，与 oHaplo 的 HSCT 相比，yMMUD 的 HSCT 中的 NRM 较低。© 2024。作者获得 Springer Nature Limited 的独家许可。
We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (<35 years) haploidentical (Haplo) donors (yHaplo) vs. 147 old (≥35 years) mismatched unrelated donors (oMMUD) (first comparison) and from 271 young (<35 years) MMUD (yMMUD) vs. 1315 old (≥35 years) Haplo donors (oHaplo) (second comparison). Acute graft-versus-host disease (aGVHD) grades II-IV were significantly lower in the yHaplo vs. oMMUD group (HR = 0.62, p = 0.007). There were no significant differences in chronic GVHD, non-relapse mortality (NRM), relapse incidence, leukemia-free survival, overall survival, and GVHD-free and relapse-free survival. As for the second comparison, more patients in the oHaplo group had de novo AML, 86.6% vs. 81.9% in the yMMUD group (p = 0.044), while myeloablative conditioning was used more frequently in the yMMUD group, 53.3% vs. 46.8% in the oHaplo group (p = 0.049). aGVHD grades II-IV and NRM were significantly lower in the yMMUD vs. oHaplo group (HR = 0.69, p = 0.013 and HR = 0.60, p = 0.022). All other transplant outcomes did not differ. In conclusion, HSCT from young alternative donors (<35 years) results in a lower incidence of grades II-IV aGVHD. In addition, NRM is lower in HSCT from yMMUD compared to HSCT from oHaplo.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.